title: Induction immunosuppression with interleukin-2 receptor antibodies (basiliximab and daclizumab) in renal transplant recipients.
authors.affiliation: Hamad Al-Essa Organ Transplant Centre, Kuwait, Kuwait.
authors.forename: M P
authors.initials: MP
authors.lastname: Nair
authors.forename: M R
authors.initials: MR
authors.lastname: Nampoory
authors.forename: K V
authors.initials: KV
authors.lastname: Johny
authors.forename: J N
authors.initials: JN
authors.lastname: Costandi
authors.forename: M
authors.initials: M
authors.lastname: Abdulhalim
authors.forename: W
authors.initials: W
authors.lastname: El-Reshaid
authors.forename: I
authors.initials: I
authors.lastname: Al-Muzairai
authors.forename: V T
authors.initials: VT
authors.lastname: Ninan
authors.forename: M
authors.initials: M
authors.lastname: Samhan
authors.forename: M
authors.initials: M
authors.lastname: Al-Mousawi
mesh_terms: D000293:Adolescent; D000328:Adult; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000077552:Basiliximab; D015897:Comorbidity; D000077561:Daclizumab; D003920:Diabetes Mellitus / Q000453:epidemiology; D005260:Female; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000517:prevention & control; D006650:Histocompatibility Testing; D006801:Humans; D006973:Hypertension / Q000150:complications; D007074:Immunoglobulin G / Q000009:adverse effects / Q000627:therapeutic use*; D007165:Immunosuppression Therapy / Q000379:methods; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D007518:Isoantibodies / Q000097:blood; D016030:Kidney Transplantation / Q000276:immunology*; D008875:Middle Aged; D017202:Myocardial Ischemia / Q000150:complications; D011993:Recombinant Fusion Proteins; D012449:Safety; D013997:Time Factors; D014184:Transplantation, Homologous
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D007518:Isoantibodies; D011993:Recombinant Fusion Proteins; D000077552:Basiliximab; D000077561:Daclizumab